Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olatorepatide in Adults With Moderate to Severe Hidradenitis Suppurativa and Overweight or Obesity
NCT07830329Phase 2Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Nov 2028
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Olatorepatide with Placebo (2 arms). Primary endpoint: Percent change in total Abscess and inflammatory Nodule count at 52 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
olatorepatide
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07830329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830329.